Ironwood Pharmaceuticals
IRWD
166 hedge funds and large institutions have $195M invested in Ironwood Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 48 reducing their positions, and 18 closing their positions.
56,558% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $26K
86% more capital invested
Capital invested by funds: $105M → $195M (+$90M)
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
7% more funds holding
Funds holding: 155 → 166 (+11)
1.17% more ownership
Funds ownership: 90.35% → 91.52% (+1.2%)
8% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 48
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$8.63M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$1.3M |
| 3 |
Jane Street
New York
|
+$596K |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$556K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$1.97M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.34M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$879K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$815K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$563K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
UBS AM
Chicago,
Illinois
| – | -$15.5K | -21,643 | Closed |
|
177
Balyasny Asset Management
Chicago,
Illinois
| – | -$12.7K | -17,743 | Closed |
|
|
FAFN
178
First Affirmative Financial Network
Colorado Springs,
Colorado
| – | -$10.7K | -14,930 | Closed |
|
|
CFM
179
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$9.57K | -13,340 | Closed |
|
180
HSBC Holdings
London,
United Kingdom
| – | -$8.69K | -12,351 | Closed |
|
181
US Bancorp
Minneapolis,
Minnesota
| – | -$7.45K | -10,383 | Closed |
|
182
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$1 | -1 | Closed |
|
|
AW
183
Avion Wealth
The Woodlands,
Texas
| – | +$422 | +408 | New |
|
IRWD Hedge Fund Activity: Q3 2025 in Review
166 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2025, worth a combined $195M — up 86% from $105M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IRWD positions and 18 closed out — a net gain of 12 holders — while 52 added to existing stakes and 48 trimmed.
The largest buyer was Bank of America, adding an estimated $8.63M. The largest seller was LSV Asset Management, exiting entirely with an estimated $1.97M sold.
- 166 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2025, up from 155 in Q2 2025.
- Funds reported $195M of Ironwood Pharmaceuticals stock for Q3 2025, up 86% quarter-over-quarter.
- 30 funds opened new Ironwood Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of +12 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2025 was Bank of America, an estimated $8.63M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2025 was LSV Asset Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q3 2025.